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Abstract: Streptococcus suis is a Gram-positive bacterium, which causes sepsis and 
meningitis in pigs and humans. This review examines the role of known S. suis virulence 
factors in adhesion and S. suis carbohydrate-based adhesion mechanisms, as well as the 
inhibition of S. suis adhesion by anti-adhesion compounds in in vitro assays.  
Carbohydrate-binding specificities of S. suis have been identified, and these studies have 
shown that many strains recognize Gal?1-4Gal-containing oligosaccharides present in host 
glycolipids. In the era of increasing antibiotic resistance, new means to treat infections are 
needed. Since microbial adhesion to carbohydrates is important to establish disease, 
compounds blocking adhesion could be an alternative to antibiotics. The use of 
oligosaccharides as drugs is generally hampered by their relatively low affinity (micromolar) 
to compete with multivalent binding to host receptors. However, screening of a library of 
chemically modified Gal?1-4Gal derivatives has identified compounds that inhibit S. suis 
adhesion in nanomolar range. Also, design of multivalent Gal?1-4Gal-containing dendrimers 
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has resulted in a significant increase of the inhibitory potency of the disaccharide. The  
S. suis adhesin binding to Gal?1-4Gal-oligosaccharides, Streptococcal adhesin P (SadP), 
was recently identified. It has a Gal?1-4Gal-binding N-terminal domain and a C-terminal 
LPNTG-motif for cell wall anchoring. The carbohydrate-binding domain has no homology 
to E. coli P fimbrial adhesin, which suggests that these Gram-positive and Gram-negative 
bacterial adhesins recognizing the same receptor have evolved by convergent evolution. 
SadP adhesin may represent a promising target for the design of anti-adhesion ligands for 
the prevention and treatment of S. suis infections. 
Keywords: bacterial adhesion; galabiose; virulence; Streptococcus suis, carbohydrate; 
adhesin; Gb3; galactose  
 
1. Introduction 
Streptococcus suis is a Gram-positive bacterium, which is an emerging cause of serious infections, 
such as meningitis, septicemia, endocarditis and pneumonia in pigs and zoonotic meningitis in  
humans [1?4]. There are currently 35 known capsular serotypes in S. suis, of which the serotype 2 
capsule (SS2) is the most virulent. Recently, multilocus sequencing has been used to more accurately 
identify the relatedness of virulent strains. Based on this, S. suis sequence type 1 and 7 (ST1 and ST7) 
have been found to be associated with the most severe infections [5]. 
Host- and tissue-specific adhesion of both the Gram-negative and Gram-positive bacteria is a 
prerequisite for infection and invasive disease [6,7]. Bacteria interact with host mucosal cells in order 
to colonize their ecological niche. Adhesion is important for avoiding the cleaning mechanisms of the 
host mucociliary system. Bacteria have evolved multiple adhesins to specifically recognize host cell 
surface carbohydrate and protein receptors [8].  
S. suis has rapidly evolved drug resistance against antibiotics by horizontal transfer [9]. Therefore, 
novel means to prevent and treat infections are needed. Anti-adhesion therapy is based on the 
inhibition of bacterial attachment to a specific receptor structure [10,11]. Once the structures of the 
receptors are known, more potent high-affinity receptor analogs can be designed. An advantage of the 
prevention of infections by receptor analogs could be that bacteria do not develop resistance, in 
contrast to the traditional bactericidal drugs. Since anti-adhesive compounds target adhesins, which are 
required for a specific colonization of the host, the mutant phenotypes of bacteria deficient in adhesion 
would be eliminated by the host.  
Previous studies have shed new light on how S. suis interacts with host cells. In many cases, 
virulence genes are involved directly or indirectly with adhesion. In this review, virulence mechanisms 
with a role in adhesion are discussed. Particularly, S. suis adhesion mechanisms that are based on the 
recognition of carbohydrate receptors, as well as the development of carbohydrate-based anti-adhesive 
compounds are reviewed.  
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2. Streptococcus suis Adhesion 
Streptococcus suis of the capsular polysaccharide type 2 is globally the most common isolate from 
both the porcine and human cases of meningitis [12]. It is typically isolated from the nasal cavity and 
tonsils of the pigs, which can carry this bacterium asymptomatically for a long period of time. The 
exact mechanisms, which trigger the infectious disease and by which S. suis invades the blood 
circulation, are not known. It is thought that S. suis colonizing the upper respiratory tract may invade 
through the respiratory epithelium or via the intestine [13]. Once the bacteria have reached the blood 
circulation, they may penetrate into the brain by adhering to brain capillary endothelial cells and cross 
the blood brain barrier. The molecular mechanisms of S. suis interaction with different tissue 
compartments and cells are poorly known. 
S. suis adhesion and invasion to the cultured epithelial cells commonly used in laboratories, such as 
A549, HeLa, MDCK and Hep-2 cells, has been studied. A polysaccharide capsule has been found to 
partially mask the adhesion [14]. The unencapsulated serotype 2 and non-typeable strains have been 
found to be more adhesive and invasive than encapsulated strains [15]. The invasion mechanisms of S. suis 
into host cells have been suggested to be closely related to other Streptococci. S. suis was described 
upon interaction with the host cell membrane to form large membrane invaginations or filopodia-like 
protrusions, followed by a process called close-contact-induced membrane-triggering [15]. 
Adhesion to the capillary endothelial cells precedes the penetration of S. suis into the brain from 
blood circulation and could be mediated by either direct invasion of bacteria into the cells by endocytic 
mechanisms or by disrupting the cell junctions. The adhesion of S. suis to the brain microvascular cells 
has been reported to be independent of the capsular polysaccharide expression. S. suis type 2 strains 
have been found to adhere to both human and porcine microvascular endothelial cells, but to invade 
only porcine cells with actin-dependent mechanisms [16]. Recently, S. suis and Neisseria meningitidis 
have been found to invade into the human choroid plexus papilloma cells and cross from the 
basolateral onto the apical side, thus modelling bacterial entry from the blood into the cerebrospinal 
side [17,18]. S. suis can also bind and activate plasminogen to proteolytically make the blood-brain 
barrier leaky to bacteria [19]. Furthermore, the S. suis polysaccharide capsule and cell wall can 
synergistically induce production of prostaglandin and metalloproteinase by macrophages and play a 
critical role in the permeabilization of the blood-brain barrier [20]. 
3. Virulence Genes with a Role in Adhesion 
3.1. Regulators 
During the colonization of the upper respiratory tract and the invasion of the blood circulation,  
S. suis needs to regulate the expression of the proteins involved in adhesion. Recent evidence shows 
that regulators required for in vivo virulence (Table 1) also modulate adhesion properties. 
The regulatory genes required for virulence have been characterized by the comparison of the 
knockout mutants and wild-type bacteria for their survival both in mice and in pig infection models. 
Several two-component regulatory systems (TCS) regulate gene expression in Streptococci, such as 
those required for the natural competence of genetic transformation and quorum sensing [21,22]. TCS 
consist of a sensor kinase protein, which phosphorylates and activates a transcriptional regulator that 
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binds to promoters to induce or repress the expression of a large number of genes [23]. An orphan  
two-component transcriptional regulator can also control the transcription of virulence genes. 
Knockout strains harboring deletion in the S. suis ciaRH [24] and in the genes revS and revSC21 
encoding orphan regulators show decreased adhesion to Hep-2 cells [25,26]. SalK/SalR is another 
recently described TCS required for the virulence of S. suis in the porcine model, but its role in the 
regulation of adhesion is not well known [27,28]. The two-component system CovR/S regulates a 
number of S. pyogenes virulence genes. S. suis has an orphan orthologue of covR, also known as csrR 
(capsule synthesis regulator), that was found to negatively modulate virulence [29]. S. pyogenes Rgg, 
also known as RopB, is a transcriptional regulator known to regulate the expression of dozens of genes 
and has been shown to repress adhesion to epithelial cells and negatively regulate virulence in a 
murine intraperitoneal model [30?33]. In S. suis, the genes, covR and rgg, are required for virulence, 
and the corresponding knockout strains show increased binding to Hep-2 cells [29,34]. 
Table 1. S. suis virulence genes with known phenotype in adhesion or interaction with host 
cells. The chromosomal locations of the genes in the genome of S. suis type 2 P1/7, GZ1 or 
ST1 [35] are indicated. 
GENE ID GENE DESIGNATION MUTANT PHENOTYPES 
Regulators with phenotype in adhesion 
SSU0944, SSU0945 ciaRH [24] Two-component regulator, decreased adhesion to Hep-2 cells 
SSU1873 not functional in P1/7, 
SSGZ1_1897 in S. suis GZ1 
revS [25] Orphan regulator, decreased adhesion to Hep-2 cells 
? revSC21 [26] Orphan regulator, decreased binding to Hep-2 cells 
SSU0376 luxS [36] Quorum sensing regulator, decreased adhesion 
SSU1789 rgg-like regulator [34] Negative transcriptional regulator, increased adhesion to Hep-2 cells 
SSU1191 covR [29] Orphan regulator, increased adhesion to Hep-2 cells 
SSU1202 ccpA [37] Carbon catabolite protein, decreased capsule thickness 
Modulators of adhesion 
SSU0516, SSU0519, SSU0520, 
SSU0517, SSU0535 
cps2B, cps2E, cps2F [15,38], cps2C [39], 
neuB [39] 
Polysaccharide synthesis genes, increased adhesion of unencapsulated 
mutants 
SSU0596, SSU1448 dltA and pgdA [40,41] Cell wall modification, upregulated upon contact with endothelial 
cells 
Moonlighting or other cell wall proteins without signal sequence and known anchoring mechanism 
SSU0187, SSGZ1_0184  dpp4 [42] Dipeptidyl peptidase IV, fibronectin binding 
SSU1320 eno [43,44] Enolase, fibronectin and plasminogen binding, recombinant protein 
inhibits adhesion to Hep-2 cells 
SSU0153 GAPDH, [45] Recombinant protein inhibits bacterial binding to porcine tracheal 
rings and Hep-2 cells 
SSU1541 gnd [46] 6-Phosphogluconate-dehydrogenase, recombinant protein inhibits 
bacterial binding to Hep-2 and HeLa cells 
SSU0157 glnA [47] Glutamine synthetase, decreased adherence to the Hep-2 cells 
SSU1127 atl, autolysin [48] Biofilm and Hep-2 cell adhesion  
SSU1311 fbps [49] Fibronectin binding 
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Table 1. Cont. 
GENE ID GENE DESIGNATION MUTANT PHENOTYPES 
LPXTG-anchored proteins 
SSU0925 srtA [50] Anchoring of cell wall proteins 
SSU0879 IgA1 protease [51,52] Degradation of IgA protecting mucosal surfaces 
SSU1474 (pseudo), SSUST1_ 
1540 in S. suis ST1 
sof [53] Lipoprotein degradation 
SSU0757 sspA, [54,55] Subtilisin-like protease, induces secretion of cytokines and 
chemokines 
SSU1143 ssa [56] Fibronectin/fibrinogen binding, reduced adhesion and invasion to 
Hep-2 cells 
An autoinducer AI-2/LuxS quorum sensing system regulates virulence and biofilm formation in 
Streptococci [57,58]. In S. suis, it positively regulates biofilm formation and adhesion to Hep-2 cells [36]. 
In addition, a deletion mutant in the gene, stp, which encodes a serine/threonine phosphatase, has been 
shown to adhere less to Hep-2 cells compared to the wild-type strain [59]. A global regulatory protein, 
called catabolite control protein, CcpA, regulates the utilization of carbohydrates by S. suis. It also 
regulates polysaccharide capsule thickness and hemolytic activity [37]. The regulation of S. suis 
capsule thickness might affect the adhesion properties. Conclusively, in S. suis, a complex network of 
regulation of virulence also modulates adhesion. 
3.2. S. suis Surface Glycoconjugates 
The S. suis capsular polysaccharide can block the adhesins at the cell surface. Unencapsulated 
strains agglutinate erythrocytes and adhere more strongly to HEp-2 cells than encapsulated strains [15,60]. 
The serotype 2 polysaccharide structure consists of the repeating unit ?(Neu5Ac?2-6Gal?1-
4GlcNAc?1-3)Gal?1-4(Gal?1-3)Rha?1-4Glc?1-?n [61]. Presence of sialic acid in S. suis capsular 
polysaccharide creates a negative charge on the bacterial surface. Therefore, it is likely that a host cell 
surface negative charge and the sialic acid containing bacterial polysaccharide form a biophysical 
repulsion strong enough to reduce adhesion of encapsulated S. suis to host cells. Recently, mutant 
strains with the deletion of genes required for serotype 2 capsular polysaccharide synthesis were found 
to be avirulent in animal models, but more adherent and invasive to Hep-2 cells [39]. 
Streptococcus agalactiae polysaccharide contains sialic acid and is important for the evasion of the 
complement and phagocytosis, but in the case of S. suis, it has been suggested that, due to the lower 
amount of sialic acid in S. suis type 2 capsule, it does not have a major role in the evasion of the 
complement [61]. Instead, the polysaccharide capsule of type 2 was previously described to be 
involved in the interaction of S. suis with macrophages. Specifically, removal of S. suis sialic acid 
reduced its binding to J774 macrophages [62]. The ligands recognizing sialic acid are not known. The 
S. suis type 2 capsular polysaccharide was recently found to prevent phagocytosis of S. suis by 
destabilizing lipid microdomains of phagocytes. The capsular polysaccharide prevented lactosylceramide 
accumulation into the phagocytic cup and the activation of lactosylceramide-lipid raft signaling 
pathways, thus inhibiting the activation of the phosphoinositide 3-kinase/Akt and p38 MAPK 
pathways required for the activation of phagocytosis [63]. The ability of S. suis to adhere to immune 
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cells and to prevent phagocytosis could be a mechanism for the bacteria to cross the  
blood-brain-barrier, as suggested by the ????????? Trojan ?????? theory [63]. 
The role of the S. suis polysaccharide capsule in the invasion of bacteria into the brain has been 
studied in an in vitro model of neutrophil transmigration. The neutrophils infected with S. suis 
transmigrated through the choroid plexus epithelial cell monolayer in an inverted Transwell system 
mimicking the blood-brain barrier [64]. Encapsulated S. suis bacteria induced the granulocytes to 
transmigrate through the porcine choroid plexus epithelial cells from their basolateral sides. This 
correlates with the theory that the influx of leukocytes into the brain is important for the development 
of meningitis. 
Mutant strains harboring deletions in the alanine-alanine ligase, dltA, and peptidoglycan N-deacetylase 
pgdA genes, required for modification of lipoteichoic acid and peptidoglycan structure, are more 
susceptible to the action of antimicrobial peptides and neutrophil killing mechanisms [40,41]. In 
addition, these genes are required for in vivo survival in animal models. Interestingly, the transcription 
of alanine-alanine ligase and peptidoglycan deacetylase were upregulated upon contact with 
endothelial cells [65]. It was suggested that the regulation of these genes can prime bacteria to be more 
resistant for neutrophil killing after they have crossed the blood-brain barrier. 
3.3. Cell Wall Proteins 
Gram-positive bacteria lack the outer membrane, and therefore, proteins either covalently or  
non-covalently attached to the cell wall have numerous possibilities to interact with host surfaces. The 
adhesins can be classified into different cell wall-bound protein classes based on their anchor 
mechanism: proteins that are cytoplasmic and are found in the cell wall fraction; proteins that are  
non-covalently attached to the cell wall and contain an N-terminal sequence for secretion; and proteins 
that are covalently linked to peptidoglycan and contain an N-terminal secretory signal sequence and a 
C-terminal LPXTG-motif [66].  
Streptococci have evolved mechanisms to adhere to the host cells utilizing moonlighting proteins, 
i.e., cell wall-attached proteins that have enzymatic activities in addition to adhesion specificities [67]. 
Several S. suis enzymes have been reported to be adhesins. Except for interactions with host 
fibronectin, the host receptors have remained unknown. Fibronectin has been found to be recognized 
by the S. suis cell wall-bound proteins, dipeptidyl peptidase IV, enolase and Fbps [42?44,49]. Enolase 
recognizes also plasminogen. Plasminogen binding, in addition to fibronectin, could cooperatively help 
to degrade extracellular matrix and fibrin and aid in the invasion of bacteria into tissues. Plasminogen 
binding seems in many Streptococci to be important in invasion [68]. The adhesion properties of 
moonlighting proteins and their ability to activate host proteases might represent an example of 
convergent evolution of bacteria to be able to use host proteases in subverting host defense mechanisms. 
Furthermore, S. suis glyceraldehyde-3-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, 
glutamine synthetase and autolysin have been identified as moonlighting adhesins [45?48,69], but their 
adhesion specificities are not known. 
LPXTG-motif containing proteins are covalently anchored to the cell wall peptidoglycan via their 
C-termini. They require a sortase enzyme that covalently attaches them to the peptidoglycan. S. suis 
housekeeping sortase A (SrtA) seems important in adhesion, since a knockout strain was shown to be 
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deficient in the adhesion to endothelial cells [50]. Recently, srtA was shown to be required for high 
virulence and adhesion to Hep-2 cells and human umbilical endothelial cells [70]. Some of the 
LPXTG-anchored proteins, such as IgA protease, serum opacity factor Sof, subtilisin-like protein SspA 
and fibronectin-binding protein Ssa are known to be required for virulence [51?56]. Several other 
LPXTG-motif proteins have been described, but relatively little is known of their role in adhesion and 
virulence (for extensive reviews, see [13,71]). 
An important group of proteins containing the LPXTG-anchor motif are pilins, which form the 
fimbrial structures, called pili, in Streptococci [66]. Typical for the fimbriae of Gram-positive bacteria 
are that the pilins are covalently linked via motifs closely resembling the LPXTG sequences. The 
linkages are catalyzed by pilus islet-specific sortases. In S. suis, the pilus islands srtBCD, srtE, srtF and 
srtG have been identified [72,73]. The SrtF cluster contains four genes encoding a putative signal 
peptidase (siF), putative ancillary (sfp2, pseudogene) and major (sfp1) pilus subunits and class C 
sortase, srtF [74]. Surprisingly sfp2, which is homologous to other Streptococcal fimbriae-associated 
adhesins, is a pseudogene, and the experiments carried with WT and sfb1 mutants indicate that S. suis 
fimbriae are indispensable for attachment to the pig brain capillary endothelial cells and for virulence 
in mouse sepsis models [74]. 
Interestingly, studies characterizing gene expression upon bacterial contact with endothelial cells 
have revealed that the mRNA levels of signal peptidase and sortase E involved in pilus synthesis were 
increased [65]. This suggests that, with the so far unknown mechanisms, S. suis can sense the contact 
with host cells and induce the expression of genes important for interaction with host cells. 
4. S. suis Carbohydrate-Specific Adhesion to Host Cells 
A limited number of S. suis carbohydrate-specific adhesion mechanisms have been described. Some 
S. suis strains recognize sialic acid-containing oligosaccharides. Bacteria bind to the terminal sialic acid in 
polylactosamine chains with the fine specificity of NeuNAc?2-3Gal?1-4GlcNAc?1-3Gal [75]. 
Recently, two S. suis LPXTG-anchored proteins have been shown to recognize host cell carbohydrates. 
One of them, protein HP0197, binds host cell surface glycosaminoglycans. The adhesin knockout 
strain had decreased binding to Hep-2 cells [76]. We have previously identified a Gal?1-Gal-binding 
activity and identified, recently, the corresponding adhesin [77,78]. The binding specificity to Gal?1-4Gal 
(galabiose) and exploitation of receptor analogs in the development of anti-adhesion compounds are 
discussed below. 
4.1. Galabiose (Gal?1-4Gal)-Specific Adhesion of S. suis 
The S. suis galabiose-specific adhesion activity was originally characterized with hemagglutination 
assay based on multivalent recognition of erythrocyte surface carbohydrates by bacterial adhesins [77]. 
Gal?1-4Gal-oligosaccharides are present in globo-series glycolipids, which are abundant in erythrocytes, 
endothelial and uroepithelial cells. Glycolipids containing the Gal?1-4Gal-sequence form the human P 
blood group system. The S. suis galabiose binding strains can be grouped into two groups based on 
their monosaccharide inhibition pattern in hemagglutination assays [77]. Type PN is inhibited by both 
galactose and N-acetylgalactosamine, whereas type PO is only inhibited by galactose. The S. suis 
hemagglutination is inhibited with oligosaccharides containing the Gal?1-4Gal structure at micromolar 
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concentrations, but only at millimolar concentrations by disaccharides containing Gal?1-3Gal or 
Gal?1-6Glc linkages [77]. Analysis of the detailed adhesion specificity toward galabiose-containing 
glycans revealed that it has the highest specificity to globotriaosylceramide GbO3, Gal?1-4Gal?1-
4Glc?1-1'Cer (the Pk antigen, Table 2). 
Table 2. Gal?1-4Gal-binding proteins a. 
Structure/Antigen a 
Ligands 
Adhesins Toxins 
GbO3 b Gal?1-4Gal?1-4Glc?1-1'Cer/Pk E. coli PapGI [79],  
S. suis SadP,  
P. aeruginosa  
Lectin I [80] 
S. dysenteriae Shiga 
toxin [81],  
E. coli verotoxin 1,  
2, 2c [82,83]  
GbO4  GalNAc?1-3Gal?1-4Gal?1-4Glc?1-1'Cer/P E. coli PapGII [79] E. coli verotoxin 2e [84] 
GbO5 GalNAc?1-3GalNAc?1-3Gal?1-4Gal?1-4Glc?1-
1'Cer/Forssman 
E. coli PapGIII [79]  
a For simplicity, blood group antigen P1, Gal?1-4Gal?1-4GlcNAc?1-4Gal?1-4Glc?1-1'Cer, is not included 
in the table; b GbO3, GbO4 and GbO5 are abbreviations for globotria-, globotetra- and globopentaosylceramides. 
Gal?1-4Gal is also recognized by E. coli PapG adhesins, Pseudomonas aeruginosa lectin I, Shiga 
toxin and verotoxins (Table 2). The globo-series glycolipid composition varies between animal 
species, and different galabiose containing glycolipids are host-specifically recognized by 
uropathogenic E. coli P fimbrial adhesins [79] and E. coli verotoxins (Table 2). 
4.2. The Galabiose-Binding Adhesin SadP 
The S. suis galabiose-specific adhesin has been isolated [78]. The adhesin was extracted from the  
S. suis cell wall with lysozyme and was captured with the pigeon ovomucoid affinity matrix. Pigeon 
ovomucoid is a strong glycoprotein inhibitor of S. suis hemagglutination, as it contains terminal  
Gal?1-4Gal-residues in its oligosaccharides [85,86]. A gene encoding the adhesin was identified as 
SSU_0253 from the S. suis serotype 2 strain P1/7 genomic sequence. Sequence analysis of the gene 
shows that it has an N-terminal signal peptide for secretion, seven C-terminal tandem repeats and an 
LPXTG-motif. An S. suis sadP knockout strain lost galabiose binding activity. A recombinant  
N-terminal domain of the adhesin recognizes Gal?1-4Gal-oligosaccharides. The adhesin was 
designated as the Streptococcal adhesin P (SadP). 
The SadP galabiose-binding domain has no significant homology to other known galabiose-binding 
proteins, including E. coli P fimbrial adhesins and Shiga toxins and verotoxins (Table 2). An identical 
S. suis protein, Fhb (HP0272), has been reported to bind to human complement factor H, which is a 
glycoprotein that regulates the complement system [87]. The factor H binding domain is located in the 
C-terminal region, which has homology to S. agalactiae IgA-binding protein [78]. The factor H 
binding protein in S. suis strain 05ZYH33 has an N-terminal domain that is identical to SadP. The  
fhb-05ZYH33 knockout strain was highly attenuated in a piglet model [87]. 
In the galabiose structure, the essential key hydroxyls for S. suis binding are HO-4', HO-6', HO-2 
and HO-3 (Figure 1), and in addition, PO strains have weak interactions with HO-3' and HO-6. The 
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combining site of type PO is more narrow on the terminal position of galactose, whereas the PN strains 
allow substitutions in the HO-3' position. The essential hydroxyls of galabiose required for the binding 
of E. coli PapG adhesins are different. E. coli PapG recognizes HO-2', HO-3', HO-4', HO-6' and HO-6 
hydroxyls in the disaccharide (Figure 1). The hydrogen bonding pattern suggests that these two 
bacterial adhesins recognize the disaccharide from different sides [77]. Conclusively, the functional 
assays with oligosaccharide derivatives and the adhesin sequence comparisons indicate that the 
galabiose binding E. coli PapG and S. suis SadP have different modes of mechanisms to interact with 
Gal?1-4Gal and represent an example of convergent evolution of bacterial adhesins toward binding to 
the same Gal?1-4Gal-receptor. 
Figure 1. (a) Hydrogen bonding patterns of S. suis PN, S. suis PO [77] and E. coli PapG 
adhesins [88,89]. Black dashed lines indicate hydrogen bonds and grey dashed lines 
indicate possible weak hydrogen bonds. Hydrogen bond directionalities have been mapped 
for the E. coli PapG class I adhesin [90], which was later confirmed by structural analysis 
of a globotetraose:papG class II adhesin complex [91]. (HBA = hydrogen bond acceptor, 
HBD = hydrogen bond donor). Derivatization with urea and ether groups at O-3 of ?-D-Gal 
[92] enhances affinity for S. suis PN and E. coli PapG, respectively (indicated with yellow 
ovals). Ether groups at O-2 of ?-D-Gal enhance binding to S. suis PN (indicated with green 
oval). (b) Space-filling models of the globotriose trisaccharide with hydroxyl oxygens 
interacting with the three adhesins shown in light pink, which illustrates the different 
epitopes recognized. (Globotriose conformation taken from the globotetraose:papG class II 
adhesin complex; pdb id 1J8R.) 
 
5. Towards the Development of Therapy Based on Prevention of Adhesion  
Carbohydrates have usually a low affinity to adhesins, partly because the O-glycosidic linkages 
between monosaccharides in oligosaccharides are very flexible. In addition, monovalent oligosaccharide 
inhibitors are inefficient for competing with the multivalent receptor interactions. Strategies to 
overcome the relatively low affinity of the lectin-carbohydrate interactions include modification of the 
hydroxyl groups of the oligosaccharide receptors and construction of multivalent carbohydrate 
dendrimers to increase the affinity [93,94]. 
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5.1. Combinatorial Libraries of Receptor Carbohydrates 
Previous data showed that S. suis galabiose binding was not dependent on the HO-3' and HO-2' 
hydroxyls of the terminal ?-galactose (Figure 1). The adhesin combining site of type PN allowed larger 
substituents in the HO-3' position of the terminal galactose, as compared to type PO adhesin. When 
large libraries of galabiose derivatives were tested for the inhibitory activity with E. coli PapG and  
S. suis SadP, galabiosides carrying aromatic structures at C1 were found to be efficient inhibitors of 
the PapG adhesin [92]. The major difference between PapG and SadP was that methoxymethylation at 
O2' and phenylurea derivatization at C3' of the terminal galactose in the galabiose disaccharide 
provided inhibitors of the S. suis type PN adhesin with nanomolar affinities. 
5.2. Dendrimers as Polyvalent Carbohydrate Inhibitors  
The mode of interaction between bacterial adhesins of S. suis and E. coli are different compared to 
Shiga-like toxins with GbO3 glycolipids. The adhesin can be inhibited with soluble oligosaccharides, 
whereas Shiga-like toxins are not inhibited and require that the receptor oligosaccharide is presented 
polyvalently. Utilizing the crystal structure of the AB5 Shiga-like toxin, a ?STARFISH? oligomeric 
water-soluble compound was designed consisting of five trisaccharides at the tip of spacers. It was 
found to occupy all five receptor binding sites and had subnanomolar inhibitory activity [95]. The 
inhibition of S. suis type PN and PO hemagglutination activities with dendrimeric galabiosides have 
been studied [96]. The inhibitions were tested under static conditions using hemagglutination in 
microtiter wells. The relative potencies of the dendrimeric compounds increased to 300?400-fold when 
galabiose was presented as a divalent compound. 
Bacteria adhere often under share stress and in dynamic flow conditions; therefore, a surface 
plasmon resonance assay has been used to analyze bacterial binding to galabiose-BSA neoglycoprotein 
under flow conditions [97]. The inhibitory activity of divalent, tetravalent and octavalent galabiose 
dendrimers were tested (Table 3). The highest relative inhibitory potency of 250 per sugar was 
obtained with the tetravalent compound as compared to the monovalent disaccharide. The potency per 
sugar of the tetravalent compound was twice that of the octavalent compound. For E. coli expressing 
an adhesin belonging to the PapGI class, which recognizes terminal Gal?1-4Gal, the inhibitory 
potency per sugar was highest for the octavalent compound, which suggests that the octavalent 
compound has more possibilities to interact with the tip-located fimbrial adhesins. 
S. suis adhesion has been successfully inhibited with galabiose-containing oligosaccharide 
derivatives, and SadP adhesin is thus a promising target for anti-adhesion therapy. Derivatives of 
galabiose, as well as polyvalent galabiose dendrimers can inhibit adhesion of S. suis in the nanomolar 
range. These results suggest that anti-adhesion therapy could be a potential alternative to antibiotics in 
the treatment of S. suis infections. 
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Table 3. Inhibitory potencies of galabiose dendrimers against S. suis and E. coli adhesion 
(modified from [98]). 
Bacterial strain and inhibitor Valency of dendrimer Relative potency Potency per sugar 
S. suis 628 a    
Monovalent 1 1 1 
Divalent, short spacer  2 13 7 
Divalent, long spacer  2 12 8 
Tetravalent 4 250 63 
Octavalent 8 310 39 
Octavalent PAMAM 8 260 32 
S. suis D282 b    
Monovalent 1 1 1 
Divalent 2 50 25 
Tetravalent 4 170 42 
Tetravalent galatriose c 4 8 2 
Octavalent 8 100 13 
E. coli PapGJ96 a    
Monovalent 1 1 1 
Divalent, short spacer arms 2 3 1 
Divalent, long spacer arms 2 3 2 
Tetravalent 4 8 2 
Octavalent 8 43 5 
Octavalent PAMAM 8 6 1 
a The IC50 values were determined in a surface plasmon resonance (SPR) assay [97]; relative potency = IC50 
or the MIC of the monovalent inhibitor divided by that of the inhibitor in question; relative potency per  
sugar = relative potency/valency; b MIC values were determined in a hemagglutination assay [99]; c other 
inhibitors were galabiose derivatives. 
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